Jonathan Goodman, MPhil

Results of a rodent model show that fibrin-specific core-shell nanogels with a tissue-type plasminogen activator warrants more study as a treatment for patients with DIC.

The risk for venous thromboembolism is steadily increasing among patients with cancer compared with the general population.

In a comprehensive evaluation, investigators assessed the efficacy and safety of 4F-PCC for oral fXa inhibitor–related emergent bleeding.

Among some patients with cancer-associated thrombosis, rivaroxaban may be a viable alternative to low-molecular-weight heparin.

Replacing DOACs with alternative parenteral antithrombotic strategies may help to prevent bleeding complications in patients with SARS-CoV-2 infection.